Ozagrel sodium 化学特性,用途語,生産方法
説明
Ozagrel sodium (ozagrel), a thromboxane A2 synthesis inhibitor, is used for patients with noncardioembolic stroke in China, Korea, and Japan. In the Japanese guideline for managing patients with acute ischemic stroke, it is recommended to start administering ozagrel for patients with noncardioembolic ischemic stroke, including atherothrombotic stroke and lacunar infarction, within 5 days after onset, using a dose of 80?mg twice a day for 14 days[1-2].
Ozagrel sodium 上流と下流の製品情報
原材料
準備製品